Bnp Paribas Asset Management Holding S.A. Bluebird Bio, Inc. Transaction History

Bnp Paribas Asset Management Holding S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 11, 2020	SELL	$46.96 - $61.67 $969,254 - $1.27 Million	-20,640 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$59.47 - $93.1 $3.41 Million - $5.34 Million	-57,364 Reduced 73.54%	20,640 $1.9 Million
Q2 2019 Aug 02, 2019	SELL	$75.84 - $105.21 $20,173 - $27,985	-266 Reduced 0.34%	78,004 $9.92 Million
Q1 2019 Apr 26, 2019	BUY	$64.44 - $104.11 $1.26 Million - $2.04 Million	19,586 Added 33.38%	78,270 $12.3 Million
Q4 2018 Feb 13, 2019	SELL	$59.1 - $93.26 $499,749 - $788,606	-8,456 Reduced 12.59%	58,684 $5.7 Million
Q3 2018 Nov 13, 2018	BUY	$88.86 - $117.49 $830,663 - $1.1 Million	9,348 Added 16.18%	67,140 $9.8 Million
Q2 2018 Aug 01, 2018	BUY	$99.64 - $127.59 $5.76 Million - $7.37 Million	57,792 New	57,792 $9.07 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Bnp Paribas Asset Management Holding S.A., based on Form 13F filings with the SEC.

Stay updated on Bnp Paribas Asset Management Holding S.A. with notifications on news.